TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06415682

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMA+M1 Transcranial Magnetic Stimulation
Description: The M1 stimulation session consisted 40 trains of 10-Hz rTMS with the protocol of 5s train session and 25s intertrain intervals. There were 4000 pulses per day for M1-LL (unilateral stimulation 2000 pulses). For SMA stimulation, a 5s burst of 10Hz rTMS was repeated 20 times (1000 pulse, 20 minutes' duration).~Patients in the Experimental group underwent ten sessions of double-site high frequency rTMS over the bilateral primary motor cortex (M1) of the lower leg and supplementary motor area (SMA).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: M1 Transcranial Magnetic Stimulation
Description: The M1 stimulation session consisted 40 trains of 10-Hz rTMS with the protocol of 5s train session and 25s intertrain intervals. There were 4000 pulses per day for M1-LL (unilateral stimulation 2000 pulses). Patients in the Active Comparator group underwent ten sessions of single-site active magnetic stimulation with high frequency rTMS over the bilateral M1 of the lower leg.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: Patients in the Sham Comparator group underwent 10 sessions of double sham rTMS on M1 of the lower leg.
Study: NCT04954339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aatezolizumab plus Bevacizumab
Description: Two cycles of naeoadjuvant atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) prior to surgical resection and four cycles of adjuvant atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) after the surgery will be administered.
Study: NCT06054724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga-Based Respiration Training
Description: The selected asanas, believed to be beneficial for urinary incontinence, will be practiced with a focus on breath. After the assessment session, participants will engage in three days of face-to-face yoga sessions. On the days when face-to-face sessions are held, participants will perform the second session on their own at home. The exercises will be progressively intensified during the 3rd and 5th weeks to ensure progression. The exercise program will be conducted at home, with approximately 20-minute sessions, twice a day, five days a week, for a total of 6 weeks.
Study: NCT06054724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates-Based Respiration Training
Description: Before starting the 6-week practice protocol, participants will be taught the transversus abdominis muscle activation and centering, pilates-specific lateral costal breathing and other key elements of pilates. Pilates exercises chosen as beneficial for urinary incontinence will be performed with a focus on breath. After the assessment session, participants will engage in three days of face-to-face pilates sessions. On the days when face-to-face sessions are held, participants will perform the second session on their own at home. The exercises will be progressively intensified during the 3rd and 5th weeks to ensure progression. The exercise program will be conducted at home, with approximately 20-minute sessions, twice a day, five days a week, for a total of 6 weeks.
Study: NCT06038721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Children
Description: The UP-C is administered in-person to parents and children over the course of up to 15 weekly group sessions, which last approximately 90 minutes each.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents
Description: The UP-A is administered to parents and teens over the course of approximately 15-24 weekly individual sessions, which last approximately 50 minutes each. Sessions can be administered in-person or online, with at least one session occurring in person.
Study: NCT06161844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide injection (HD1916)
Description: Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks Other Name: HD1916

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ozempic®
Description: Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks Other Name: Ozempic Injectable Product
Study: NCT06635317

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 100 mg/day orally for 25 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enoxaparin
Description: 40 mg/day subcutaneously for 28 days, with the dose reduced to 20 mg for patients weighing less than 50 kg or with an estimated glomerular filtration rate less than 30 mL/min/1.73 m².
Study: NCT06635096

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multimodal Tumor Thermal Therapy System (Shanghai MAaGI Medical Technology Co., Ltd.)
Description: These patients will receive multimodal thermal therapy using Multimodal Tumor Thermal Therapy System.
Study: NCT06636448

Intervention type: PROCEDURE
Intervention: the effect of body mass index during low-flow anesthesia
Description: The investigator planned to evaluate the effect of body mass index on patient outcomes during low-flow anesthesia in patients undergoing gynecologic cancer surgery.
Study: NCT06634628

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radioligand [11C]CHDI-00491009
Description: Intravenous injection of radioligand in the arm with PET imaging of the brain.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radioligand [11C]CHDI-00491009
Description: Intravenous injection of radioligand in the arm with PET imaging of the brain.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radioligand [11C]CHDI-00491009
Description: Intravenous injection of radioligand in the arm with PET imaging of the brain.
Study: NCT05304884

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: combined oxygen-ozone and corticosteroid
Description: Subacromial injection using Ultrasound

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: combined oxygen-ozone and corticosteroid
Description: Subacromial injection using Ultrasound

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: combined oxygen-ozone and corticosteroid
Description: Subacromial injection using Ultrasound
Study: NCT06644391

Intervention type: DIAGNOSTIC_TEST
Intervention: Carebot AI Bones
Description: The use of a deep learning-based artificial intelligence software, Carebot AI Bones version 1.2.2, designed to aid in the detection of fractures on musculoskeletal radiographs. The AI model analyzes digital X-ray images to identify fractures, highlighting areas of interest with bounding boxes.
Study: NCT05191225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RiTUXimab Injection [Truxima]
Description: 375 (mg/m2) / 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RiTUXimab Injection [Truxima]
Description: 375 (mg/m2) / 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RiTUXimab Injection [Truxima]
Description: 375 (mg/m2) / 30 minutes
Study: NCT05499975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-reported online geriatric assessment (CHAMP)
Description: The CHAMP tool is a self reported online tool that has been developed to increase patients' accessibility to geriatric assessment and improve treatment decision making. The tool includes questions about function, mobility, cognition, nutrition, social support, depression substance use disorders, and miscellaneous items. Based on usability testing in the previous phase of this study, the tool can be completed in approximately 10-15 minutes. The tool generates a summary report with recommendations for patients and clinicians.
Study: NCT05890053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK16149 40mg BID
Description: HSK16149 40mg ， orally twice a day, treatment period; 52-weeks fixed dose.
Study: NCT06013020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOAC+DAPT
Description: Century Clot-guided rivaroxaban plus DAPT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAPT
Description: Standard DAPT for 1 month, following lower-dose ticagrelor or clopidogrel plus aspirin for 11 months.
Study: NCT06069765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TUPEX
Description: This program contains exercises with their own body weight or with Thera-bands for gaining strength in their shoulder and trunk muscles. It contains some progression exercise if needed.~Each session can last between 20 and 30 minutes. Children have to do each session three times a week during 8 weeks.
Study: NCT06544772

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pivot cigarette smoking cessation program
Description: The Pivot cigarette smoking cessation program comprises a mobile personal breath carbon monoxide sensor (Pivot Breath Sensor) and a smartphone app (Pivot app) with in-app asynchronous SMS text-based coaching with a certified human tobacco cessation coach.
Study: NCT05745064

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TL-925
Description: TL-925 is an eye drop.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
Study: NCT05469893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Oral, dosage and timing per protocol design

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Oral, dosage and timing per protocol design
Study: NCT05374317

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow Fever Vaccine
Description: Administered subcutaneously once.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow Fever Vaccine
Description: Administered subcutaneously once.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Yellow Fever Vaccine
Description: Administered subcutaneously once.
Study: NCT05958043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D- printed Full-arch Implant-supported Provisionals Restorations
Description: The full-arch provisional restorations will be placed on dental implants that should be positioned to allow for the fabrication of a prosthesis that spans at least 12 units (from the right first molar to the left first molar, accepting distal extensions). Before completing the essential clinical data registration to produce an individual patient-oriented prosthesis, trans-epithelial abutments will be put at the torque the manufacturer recommends (30-35 Ncm typically), according to the appropriate gingival height.~At visit three, the full-arch provisional will be screwed in using the manufacturer's specified torque (15 Ncm typically). For 12 to 15 weeks (about three months), the patient will be in the preliminary phase, during which time data will be gathered. Once the stipulated time has elapsed, the definitive prosthesis in monolithic zirconia prosthesis will be placed.

Intervention type: DEVICE
Group type: OTHER
Intervention: CAD/CAM-milled Full-arch Implant-supported Provisionals Restorations
Description: The full-arch provisional restorations will be placed on dental implants that should be positioned to allow for the fabrication of a prosthesis that spans at least 12 units (from the right first molar to the left first molar, accepting distal extensions). Before completing the essential clinical data registration to produce an individual patient-oriented prosthesis, trans-epithelial abutments will be put at the torque the manufacturer recommends (30-35 Ncm typically), according to the appropriate gingival height.~At visit three, the full-arch provisional will be screwed in using the manufacturer's specified torque (15 Ncm typically). For 12 to 15 weeks (about three months), the patient will be in the preliminary phase, during which time data will be gathered. Once the stipulated time has elapsed, the definitive prosthesis in monolithic zirconia prosthesis will be placed.
Study: NCT06542848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy and Rehabilitation Practices
Description: The treatment program consisted of 3 sessions per week, each lasting 45 minutes. The rehabilitation program included 30 minutes of conventional TENS application to the wrist extensor muscles and quadriceps muscle, upper and lower extremity exercises, balance and coordination exercises, and weight transfer exercises. The upper extremity exercises consisted of range of motion exercises for the shoulder joint, while the lower extremity exercises included range of motion exercises for the hip, knee, and ankle joints. Balance exercises included forward, backward, and lateral leaning exercises, as well as weight transfer and stepping exercises in all directions. The treatment duration was planned to be a total of 24 sessions over 8 weeks. Evaluations were conducted before and after the treatment program.
Study: NCT06213883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biobehavioral Response to in-lab exposure to physical activity
Description: ED severity, biological and affective markers of physical activity response, and both exercise-specific and general positive (reward) and negative (avoidance/escape) valence sensitivities associate with physical activity will be comprehensively examined.
Study: NCT04725721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FIRST
Description: FIRST is built upon five empirically supported principles of change (ESPCs-i.e., feeling calm, increasing motivation, repairing thoughts, solving problems, trying the opposite). Each principle can be applied to treatment of problems spanning depression, anxiety (including OCD and PTS), and conduct problems-thus encompassing a majority of the youths seen in outpatient care. Its design addresses breadth of problem coverage, youth comorbidity, and flux in youth treatment needs during episodes of care. It is used in conjunction with performance feedback via a web-based tracking system that gives clinicians weekly data on youth treatment response. FIRST has treatment and training efficiency, and efficient clinician skill-building is supported by group consultation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Treatment in the usual care (UC) condition will use the clinical procedures therapists consider appropriate and believe to be effective.
Study: NCT06435871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expanded Prostate Cancer Index Composite and Decision Regret Scale
Description: This comprehensive instrument measures urinary, sexual, and bowel symptoms in men treated for prostate cancer. It can provide a detailed view of the patient's quality of life post-treatment.
Study: NCT05853913

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise will be walking/jogging at a medium to hard intensity for 1 hour.
Study: NCT04724655

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gastric lavage with paraffin oil and bicarbonate
Description: Gastric lavage will be initiated with 50 mL of Paraffin oil and 50 mL of sodium bicarbonate solution 8.4%, then aspiration will be done after 3-5 min through nasogastric tube
Study: NCT05426252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Abatacept, co-stimulation blockade, to be given for GVHD prophylaxis in combination with sirolimus post allogeneic hematopoietic stem cell transplantation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus, mTOR inhibitor, to be given for GVHD prophylaxis in combination with abatacept post allogeneic hematopoietic stem cell transplantation.
Study: NCT05841381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: pyrotinib: 400mg orally daily for 1 year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 17 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 17 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80mg/m2 per week for a total of 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80mg/m2 per week for a total of 12 weeks
Study: NCT06085482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-LY3502970
Description: Administered IV
Study: NCT04198350

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Islet implantation
Description: Transplantation of allogeneic pancreatic human islets will be performed into the anterior chamber of a single eye with the poorest visual acuity (see inclusion/exclusion criteria below). Up to 40 000 IEQ of islets in a maximum volume of 350µl will be transplanted.
Study: NCT04933669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib neoadjuvant therapy
Study: NCT05215041

Intervention type: OTHER
Intervention: Non intervention
Description: If the vaginal delivery is failed after spontaneous labor for up to 24h, they will receive cesarean section

Intervention type: OTHER
Intervention: Non intervention
Description: If the vaginal delivery is failed after spontaneous labor for up to 24h, they will receive cesarean section
Study: NCT04803058

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCD601
Description: Investigational Product
Study: NCT05653050

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CamAPS HX
Description: Fully automated closed-loop system (CamAPS HX) with ultra-rapid insulin aspart.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard insulin pump therapy with CGM
Description: Participants usual insulin pump therapy with Freestyle Libre 3 CGM
Study: NCT05959057

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ERr 731 - Micro-coated
Description: natural extract of the Rheum Rhaponticum L plant (Siberian rhubarb). The primary active constituents of ERr 731® are hydroxystilbenes, primarily rhaponticin and desoxyrhaponticin.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ERr 731 - Micro-coated
Description: natural extract of the Rheum Rhaponticum L plant (Siberian rhubarb). The primary active constituents of ERr 731® are hydroxystilbenes, primarily rhaponticin and desoxyrhaponticin.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ERr 731 - Enteric coated
Description: natural extract of the Rheum Rhaponticum L plant (Siberian rhubarb). The primary active constituents of ERr 731® are hydroxystilbenes, primarily rhaponticin and desoxyrhaponticin.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ERr 731 - Enteric coated
Description: natural extract of the Rheum Rhaponticum L plant (Siberian rhubarb). The primary active constituents of ERr 731® are hydroxystilbenes, primarily rhaponticin and desoxyrhaponticin.
Study: NCT03284073

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterus transplantation
Description: Transplantation of the uterus from a live donor and IVF treatment
Study: NCT06536920

Intervention type: DIAGNOSTIC_TEST
Intervention: Migraine screening questionnaire
Description: Screening test
Study: NCT06536829

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofacial release technique and sciatic nerve slider technique
Description: Myofacial release technique, sciatic nerve slider technique 0 week,6 week 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofacial release technique and sciatic nerve slider technique
Description: Myofacial release technique, sciatic nerve slider technique 0 week,6 week 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofacial release technique
Description: 0week,6 week, 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofacial release technique
Description: 0week,6 week, 12 weeks
Study: NCT06542328

Intervention type: DEVICE
Intervention: ERI CVX-air portable X-ray system
Description: investigational device

Intervention type: DEVICE
Intervention: ERI CVX-air portable X-ray system
Description: investigational device

Intervention type: DEVICE
Intervention: Samsung GM85 (K180543) or MobileDaRt Evolution (K080701)
Description: The commercially available comparator equipment used for pulmonology.

Intervention type: DEVICE
Intervention: Samsung GC85A (K160997) or Fujifilm FDR Smart X (K212956)
Description: The commercially available comparator equipment used for Orthopaedic.
Study: NCT05433818

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group A
Description: Skin-to-Skin Contact (SSC) contributes to mother-infant interaction and can increase breastfeeding success

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group B
Description: education with a structured and expert opinion-based breastfeeding brochure
Study: NCT04724655

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gastric lavage with coconut oil and bicarbonate
Description: Gastric lavage will be initiated with 50 ml coconut oil and 50 ml sodium bicarbonate 8.4 % then aspiration will be done after 3-5 min through nasogastric tube

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: inotropes as levophid, fluids and electrolytes , endotracheal intubation, mechanical ventilation and antiarrhythmic agents as Magnesium sulfate

Intervention type: DRUG
Group type: OTHER
Intervention: standard treatment
Description: inotropes as levophid, fluids and electrolytes , endotracheal intubation, mechanical ventilation and antiarrhythmic agents as Magnesium sulfate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: inotropes as levophid, fluids and electrolytes , endotracheal intubation, mechanical ventilation and antiarrhythmic agents as Magnesium sulfate

Intervention type: OTHER
Group type: OTHER
Intervention: gastric lavage with saline and bicarbonate
Description: Gastric lavage with saline and sodium bicarbonate 8.4% then aspiration will be done after 3-5 min through nasogastric tube